

Puma Biotechnology

Earnings Call

Commercial Update



May 7, 2026

nerlynx[®]
(neratinib) tablets




Forward-Looking Safe-Harbor Statement

This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.




Puma's Pharmacy and Distributor Network



\$42.0 Million Net NERLYNX Revenue in Q1'26


~3% decrease in Q1'26 compared to Q1'25



Inventory Change (\$)

Q1'25	Q1'26
-\$4.7 mil	-\$7.9 mil

~30% decrease in Q1'26 compared to Q4'25




Inventory Change (\$)

Q4'25	Q1'26
\$5.7 mil	-\$7.9 mil

2,328 Ex-Factory Bottles Were Sold in Q1'26


~0.4% decrease in Q1'26 compared to Q1'25



Inventory Change Bottles

Q1'25	Q1'26
-251	-439

~29% decrease in Q1'26 compared to Q4'25




Inventory Change Bottles

Q4'25	Q1'26
343	-439








~78% of Patients in Q1'26 Started at a Reduced Dose*

% of Patients Starting at Reduced Dose



*Reduced dose defined as fewer than 6 pills per day

Rest of World Partnerships – Timelines

Region	Partner	Regulatory Approvals	Commercial Launches
Australia / SE Asia	 Specialised Therapeutics	<ul style="list-style-type: none"> • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand • 2022 – Ext. Adj. in the Philippines; mBC in Singapore • 2023 – mBC in Malaysia • 2024 – Ext. Adj. and mBC in Thailand 	<ul style="list-style-type: none"> • 2020 – Singapore • 2021 – Malaysia, Brunei, New Zealand • Q1 2026 - Thailand
Israel	 MEDISON Delivering Innovative Healthcare	<ul style="list-style-type: none"> • 2020 – Approved in Ext. Adj. and mBC 	<ul style="list-style-type: none"> • 2020 – Launched
Canada	 Knight	<ul style="list-style-type: none"> • 2019 – Ext. Adj. approved • 2021 – mBC approved 	<ul style="list-style-type: none"> • 2020 – Launched
Latin America	 PINT PHARMA	<ul style="list-style-type: none"> • 2019 – Ext Adj in Argentina • 2020 – Ext. Adj in Chile, Ecuador; mBC in Argentina • 2021 – Ext Adj. and mBC in Peru; mBC in Chile; Ext. Adj. in Brazil • 2022 – Ext. Adj. in Mexico; mBC in Ecuador • 2023 – mBC in Colombia and Mexico • 2024 – mBC in Brazil 	<ul style="list-style-type: none"> • 2020 – Argentina • 2021 – Chile and Peru • 2022 – Brazil • 2023 – Mexico and Colombia
Europe Greater China Middle East North and West Africa South Africa Turkey	 Pierre Fabre	<ul style="list-style-type: none"> • 2019 – Ext. Adj. EMA and Hong Kong • 2020 – Ext. Adj. in China, Taiwan • 2021 – mBC in Taiwan • 2023 – Ext. Adj. in Morocco, South Africa, and UAE • 2024 – Ext. Adj. in Syria, Saudi Arabia, Algeria, Turkey • 2025 – Ext. Adj. in Lebanon 	<ul style="list-style-type: none"> • 2019 – Germany, UK, Austria • 2020 – Sweden, Finland, Scotland, Switzerland, Denmark, HK • 2021 – China, Taiwan, Greece, Czech Republic, Luxembourg • 2022 – Ireland, Spain • 2023 – Slovakia • 2024 – Morocco, South Africa, UAE, Turkey, Saudi Arabia • 2025 – Libya, Algeria
South Korea	 BIXINK THERAPEUTICS	<ul style="list-style-type: none"> • 2021 – Ext. Adj. in S. Korea 	<ul style="list-style-type: none"> • 2022 – Launched
Russia/CIS	 TERKIM	<ul style="list-style-type: none"> • Distribution agreement executed 	

Puma Biotechnology

Earnings Call

Commercial Update



May 7, 2026

nerlynx[®]
(neratinib) tablets

